SCHEMBL95975

SCHEMBL95975

[CH2]c1ccc(C(=O)N(C)c2ccncc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.65
KMT2A Q03164 2/20 0.65
MLYCD O95822 1/20 0.52
PDE10A Q9Y233 2/20 0.47
NAMPT P43490 1/20 0.47
LMNA P02545 2/20 0.45
HTT P42858 1/20 0.44
HSD17B10 Q99714 1/20 0.43
GRM1 Q13255 5/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
RAB9A P51151 1/20 0.43
NR1H3 Q13133 1/20 0.41
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
CHRM5 P08912 1/20 0.41
CHKA P35790 1/20 0.41
MAOA P21397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29123175 0.87 KDM4E (0.82) KDM4EKMT2AMLYCDPDE10ANAMPT
SCHEMBL96022 0.81 TRPV1 (0.62) KDM4EKMT2AMLYCDHTTHSD17B10
SCHEMBL97673 0.79 EGFR (0.48) KDM4EKMT2ALMNAHTTGRM1
SCHEMBL12812295 0.79 KDM4E (0.59) KDM4EKMT2AMLYCDPDE10ANAMPT
SCHEMBL8012222 0.79 KMT2A (0.59) KDM4EKMT2APDE10AHTTNPC1
SCHEMBL10801846 0.79 KDM4E (1.00) KDM4EKMT2AMLYCDPDE10ALMNA
SCHEMBL3932273 0.76 MLYCD (0.44) KDM4EKMT2AMLYCDPDE10ANAMPT
SCHEMBL429504 0.74 KDM4E (0.52) KDM4EKMT2AMLYCDPDE10ANAMPT
SCHEMBL40709 0.73 ALDH1A1 (0.59) KDM4EKMT2ALMNAHTTHSD17B10
SCHEMBL3939111 0.72 TSHR (0.46) KDM4EKMT2ALMNAHSD17B10GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB KDM4E 1125/4885KMT2A 1059/4885MLYCD 4635/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 KDM4E 3919/4885KMT2A 2732/4885MLYCD 3616/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 KDM4E 3919/4885KMT2A 2732/4885MLYCD 3616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.